Impact of oral glucocorticoids on the effectiveness of romosozumab: the multicenter OASIS cohort study
Authors' conclusion
Oral GC use did not significantly affect changes in BTMs or BMD increases at the lumbar spine. Smaller gains in total hip BMD were observed in GC users, which may have reflected not only GC use but also underlying disease-related factors.
Study context
- Population
- Patients treated with romosozumab who completed 12 months of therapy (95.3% female, mean age 76.6 years; mean lumbar spine T-score −2.7)IPTW pseudo-population
- Participants
- 428 patients
- Exposure
- Oral glucocorticoids (GC) users vs non-users receiving romosozumab
- GC usersn = 40
- Non-usersn = 39.8reference
- Outcome
- Percentage changes in bone turnover markers (BTMs) and BMD
- Follow-up
- 12 months
Methodological detailsmulticentre, inverse probability of treatment weighting, multivariable analysis
- Multicentre
- Inverse probability of treatment weighting
- Multivariable analysis
Main finding
As reported in the abstract
- GC use did not significantly affect the changes in PINP and TRACP-5b levels
Observational data: associations, not effects.
Further findings
Lumbar spine BMD increase · 12 months · comparable between groups
P = 0.55
Total hip BMD increase · 12 months · significantly lower in GC users
P = 0.003
Factors associated with bone mineral density (BMD) increase (multivariable)
- Baseline PINP significantly associated with lumbar spine BMD increase; daily GC dose a significant factor for total hip
Original publication
Impact of oral glucocorticoids on the effectiveness of romosozumab: the multicenter OASIS cohort study. Osteoporos Int. Published 8 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →